Novartis Steers Zolgensma Towards Commercial Success In Europe
Gene Therapy Reimbursed In UK And Italy
The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.
